Restriction factors in HIV-1 disease progression

Current HIV Research

Volumn 13, Issue 6, 2015, Pages 448-461

  Merindol, Natacha ^a   Berthoux, Lionel ^a  

^a UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

Author keywords

APOBEC3A H; Elite controllers; HIV; MxB Mx2; P21 CDKN1; SAMHD1; Slow progressors; Tetherin Bst2; TRIM22 Staf50; TRIM5

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYCLIN DEPENDENT KINASE 9; INTERFERON; MYXOVIRUS RESISTANCE PROTEIN; P21 ACTIVATED KINASE; PROTEIN; SAMHD1 PROTEIN; TETHERIN PROTEIN; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG;

AICARDI GOUTIERES SYNDROME; ALLELE; ANTIVIRAL ACTIVITY; ARTICLE; DISEASE COURSE; ENDOCYTOSIS; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE EVASION; INFECTION CONTROL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN POLYMORPHISM; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS CAPSID; VIRUS LOAD; VIRUS REPLICATION; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRUS REPLICATION;

EID: 84940948407     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X13666150608104412     Document Type: Article

References (196)

1. http://www.who.int/mediacentre/factsheets/fs360/en/
2. Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. Aids. 2010; 24(10): 1598-601.
3. Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013; 9(3): e1003211.
4. Persaud, D. in 20th International AIDS Conference. Symposium presentation MOSY0501 (International AIDS Society, 2014).; Henrich, 2014 #4
5. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95(15): 8869-73.
6. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. The Journal of infectious diseases. 2005; 191(9): 1410-8.
7. Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(24): 9523-8.
8. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997; 387(6629): 183-8.
9. Coffin J, Swanstrom R. HIV pathogenesis: dynamics and genetics of viral populations and infected cells. Cold Spring Harbor perspectives in medicine. 2013; 3(1): a012526.
10. Madec Y, Boufassa F, Avettand-Fenoel V, Hendou S, Melard A, Boucherit S, et al. Early control of HIV-1 infection in long-term nonprogressors followed since diagnosis in the ANRS SEROCO/HEMOCO cohort. Journal of acquired immune deficiency syndromes. 2009; 50(1): 19-26.
11. Rodes B, Toro C, Paxinos E, Poveda E, Martinez-Padial M, Benito JM, et al. Differences in disease progression in a cohort of longterm non-progressors after more than 16 years of HIV-1 infection. Aids. 2004; 18(8): 1109-16.
12. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D. Prevalence and comparative characteristics of longterm nonprogressors and HIV controller patients in the French Hospital Database on HIV. Aids. 2009; 23(9): 1163-9.
13. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, et al. A systematic review of definitions of extreme phenotypes of HIV control and progression. Aids. 2014; 28(2): 149-62.
14. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science. 2007; 317(5840): 944-7.
15. International HIVCS, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010; 330(6010): 1551-7.
16. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. Journal of virology. 2008; 82(11): 5398-407.
17. Dyer WB, Zaunders JJ, Yuan FF, Wang B, Learmont JC, Geczy AF, et al. Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection. Retrovirology. 2008; 5: 112.
18. Ferre AL, Hunt PW, McConnell DH, Morris MM, Garcia JC, Pollard RB, et al. HIV controllers with HLA-DRB1*13 and HLADQB1* 06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. Journal of virology. 2010; 84(21): 11020-9.
19. Vingert B, Perez-Patrigeon S, Jeannin P, Lambotte O, Boufassa F, Lemaitre F, et al. HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog. 2010; 6(2): e1000780.
20. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity. 2008; 29(6): 1009-21.
21. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(16): 6776-81.
22. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med. 1997; 3(2): 205-11.
23. Ciuffi A, Bleiber G, Munoz M, Martinez R, Loeuillet C, Rehr M, et al. Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. Journal of virology. 2004; 78(19): 10747-54.
24. Saez-Cirion A, Hamimi C, Bergamaschi A, David A, Versmisse P, Melard A, et al. Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood. 2011; 118(4): 955- 64.
25. Sawyer SL, Emerman M, Malik HS. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2004; 2(9): E275.
26. Sawyer SL, Wu LI, Emerman M, Malik HS. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(8): 2832-7.
27. Lim ES, Fregoso OI, McCoy CO, Matsen FA, Malik HS, Emerman M. The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. Cell host & microbe. 2012; 11(2): 194-204.
28. Busnadiego I, Kane M, Rihn SJ, Preugschas HF, Hughes J, Blanco- Melo D, et al. Host and viral determinants of Mx2 antiretroviral activity. Journal of virology. 2014; 88(14): 7738-52.
29. Lim ES, Malik HS, Emerman M. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses. Journal of virology. 2010; 84(14): 7124-34.
30. Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. The Journal of clinical investigation. 2011; 121(4): 1549-60.
31. Wu L. SAMHD1: a new contributor to HIV-1 restriction in resting CD4+ T-cells. Retrovirology. 2012; 9: 88.
32. Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y, et al. SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology. 2012; 9: 87.
33. Pan X, Baldauf HM, Keppler OT, Fackler OT. Restrictions to HIV- 1 replication in resting CD4+ T lymphocytes. Cell Res. 2013; 23(7): 876-85.
34. Nisole S, Stoye JP, Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol. 2005; 3(10): 799-808.
35. Han K, Lou DI, Sawyer SL. Identification of a genomic reservoir for new TRIM genes in primate genomes. PLoS genetics. 2011; 7(12): e1002388.
36. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004; 427(6977): 848-53.
37. Battivelli E, Lecossier D, Matsuoka S, Migraine J, Clavel F, Hance AJ. Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. Journal of virology. 2010; 84(21): 11010-9.
38. Battivelli E, Migraine J, Lecossier D, Yeni P, Clavel F, Hance AJ. Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity. Journal of virology. 2011; 85(22): 11846-54.
39. Kaumanns P, Hagmann I, Dittmar MT. Human TRIM5alpha mediated restriction of different HIV-1 subtypes and Lv2 sensitive and insensitive HIV-2 variants. Retrovirology. 2006; 3: 79.
40. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(14): 5514-9.
41. Kutluay SB, Perez-Caballero D, Bieniasz PD. Fates of Retroviral Core Components during Unrestricted and TRIM5-Restricted Infection. PLoS Pathog. 2013; 9(3): e1003214.
42. Diaz-Griffero F, Li X, Javanbakht H, Song B, Welikala S, Stremlau M, et al. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology. 2006; 349(2): 300-15.
43. Rold CJ, Aiken C. Proteasomal degradation of TRIM5alpha during retrovirus restriction. PLoS Pathog. 2008; 4(5): e1000074.
44. Mandell MA, Jain A, Arko-Mensah J, Chauhan S, Kimura T, Dinkins C, et al. TRIM proteins regulate autophagy and can target autophagic substrates by direct recognition. Developmental cell. 2014; 30(4): 394-409.
45. Roa A, Hayashi F, Yang Y, Lienlaf M, Zhou J, Shi J, et al. RING domain mutations uncouple TRIM5alpha restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating. Journal of virology. 2012; 86(3): 1717-27.
46. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(19): 7465-70.
47. Pertel T, Hausmann S, Morger D, Zuger S, Guerra J, Lascano J, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature. 2011; 472(7343): 361-5.
48. Nepveu-Traversy ME, Berthoux L. The conserved sumoylation consensus site in TRIM5alpha modulates its immune activation functions. Virus research. 2014; 184C: 30-8.
49. Tareen SU, Emerman M. Human Trim5alpha has additional activities that are uncoupled from retroviral capsid recognition. Virology. 2011; 409(1): 113-20.
50. Uchil PD, Hinz A, Siegel S, Coenen-Stass A, Pertel T, Luban J, et al. TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. Journal of virology. 2013; 87(1): 257-72.
51. Sivro A, Su RC, Plummer FA, Ball TB. HIV and interferon regulatory factor 1: a story of manipulation and control. AIDS research and human retroviruses. 2013; 29(11): 1428-33.
52. Sewram S, Singh R, Kormuth E, Werner L, Mlisana K, Karim SS, et al. Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection. The Journal of infectious diseases. 2009; 199(11): 1657-63.
53. Speelmon EC, Livingston-Rosanoff D, Li SS, Vu Q, Bui J, Geraghty DE, et al. Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. Journal of virology. 2006; 80(5): 2463-71.
54. van Manen D, Rits MA, Beugeling C, van Dort K, Schuitemaker H, Kootstra NA. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog. 2008; 4(2): e18.
55. Goldschmidt V, Bleiber G, May M, Martinez R, Ortiz M, Telenti A, et al. Role of common human TRIM5alpha variants in HIV-1 disease progression. Retrovirology. 2006; 3: 54.
56. Javanbakht H, An P, Gold B, Petersen DC, O'Huigin C, Nelson GW, et al. Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology. 2006; 354(1): 15-27.
57. Sawyer SL, Wu LI, Akey JM, Emerman M, Malik HS. Highfrequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans. Current biology: CB. 2006; 16(1): 95-100.
58. Nakayama EE, Carpentier W, Costagliola D, Shioda T, Iwamoto A, Debre P, et al. Wild type and H43Y variant of human TRIM5alpha show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro. Immunogenetics. 2007; 59(6): 511-5.
59. Liu FL, Qiu YQ, Li H, Kuang YQ, Tang X, Cao G, et al. An HIV-1 resistance polymorphism in TRIM5alpha gene among Chinese intravenous drug users. Journal of acquired immune deficiency syndromes. 2011; 56(4): 306-11.
60. Price H, Lacap P, Tuff J, Wachihi C, Kimani J, Ball TB, et al. A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort. Aids. 2010; 24(12): 1813-21.
61. de Masson A, Kirilovsky A, Zoorob R, Avettand-Fenoel V, Morin V, Oudin A, et al. Blimp-1 overexpression is associated with low HIV-1 reservoir and transcription levels in central memory CD4+ T cells from elite controllers. Aids. 2014; 28(11): 1567-77.
62. Graf EH, Mexas AM, Yu JJ, Shaheen F, Liszewski MK, Di Mascio M, et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS pathogens. 2011; 7(2): e1001300.
63. Granier C, Battivelli E, Lecuroux C, Venet A, Lambotte O, Schmitt-Boulanger M, et al. Pressure from TRIM5alpha contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles. Journal of virology. 2013; 87(18): 10368-80.
64. Durand CM, O'Connell KA, Apuzzo LG, Langan SJ, Imteyaz H, Ahonkhai AA, et al. HIV-1 Gag evolution in recently infected human leukocyte antigen-B*57 patients with low-level viremia. Aids. 2010; 24(15): 2405-8.
65. Payne RP, Branch S, Kloverpris H, Matthews PC, Koofhethile CK, Strong T, et al. Differential escape patterns within the dominant HLA-B*57: 03-restricted HIV Gag epitope reflect distinct cladespecific functional constraints. Journal of virology. 2014; 88(9): 4668-78.
66. Aviv T, Lin Z, Lau S, Rendl LM, Sicheri F, Smibert CA. The RNA-binding SAM domain of Smaug defines a new family of post-transcriptional regulators. Nature structural biology. 2003; 10(8): 614-21.
67. White TE, Brandariz-Nunez A, Valle-Casuso JC, Amie S, Nguyen L, Kim B, et al. Contribution of SAM and HD domains to retroviral restriction mediated by human SAMHD1. Virology. 2013; 436(1): 81-90.
68. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, et al. Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nature genetics. 2009; 41(7): 829-32.
69. Brandariz-Nunez A, Valle-Casuso JC, White TE, Laguette N, Benkirane M, Brojatsch J, et al. Role of SAMHD1 nuclear localization in restriction of HIV-1 and SIVmac. Retrovirology. 2012; 9: 49.
70. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med. 2012; 18(11): 1682-7.
71. Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam AR, Lee KY, et al. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. The Journal of biological chemistry. 2004; 279(49): 51545-53.
72. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature. 2010; 467(7312): 214-7.
73. St Gelais C, de Silva S, Amie SM, Coleman CM, Hoy H, Hollenbaugh JA, et al. SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+ T-lymphocytes cannot be upregulated by interferons. Retrovirology. 2012; 9: 105.
74. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature. 2011; 480(7377): 379-82.
75. Rehwinkel J, Maelfait J, Bridgeman A, Rigby R, Hayward B, Liberatore RA, et al. SAMHD1-dependent retroviral control and escape in mice. The EMBO journal. 2013; 32(18): 2454-62.
76. Pauls E, Ruiz A, Riveira-Munoz E, Permanyer M, Badia R, Clotet B, et al. p21 regulates the HIV-1 restriction factor SAMHD1. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(14): E1322-4.
77. White TE, Brandariz-Nunez A, Valle-Casuso JC, Amie S, Nguyen LA, Kim B, et al. The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation. Cell host & microbe. 2013; 13(4): 441-51.
78. Welbourn S, Dutta SM, Semmes OJ, Strebel K. Restriction of virus infection but not catalytic dNTPase activity is regulated by phosphorylation of SAMHD1. Journal of virology. 2013; 87(21): 11516-24.
79. Ryoo J, Choi J, Oh C, Kim S, Seo M, Kim SY, et al. The ribonuclease activity of SAMHD1 is required for HIV-1 restriction. Nat Med. 2014; 20(8): 936-41.
80. Dragin L, Nguyen LA, Lahouassa H, Sourisce A, Kim B, Ramirez BC, et al. Interferon block to HIV-1 transduction in macrophages despite SAMHD1 degradation and high deoxynucleoside triphosphates supply. Retrovirology. 2013; 10: 30.
81. Kyei GB, Cheng X, Ramani R, Ratner L. Cyclin L2 Is a Critical HIV Dependency Factor in Macrophages that Controls SAMHD1 Abundance. Cell host & microbe. 2015; 17(1): 98-106.
82. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nature immunology. 2012; 13(3): 223-8.
83. Behrendt R, Schumann T, Gerbaulet A, Nguyen LA, Schubert N, Alexopoulou D, et al. Mouse SAMHD1 has antiretroviral activity and suppresses a spontaneous cell-intrinsic antiviral response. Cell reports. 2013; 4(4): 689-96.
84. Allouch A, David A, Amie SM, Lahouassa H, Chartier L, Margottin-Goguet F, et al. p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(42): E3997-4006.
85. White TE, Brandariz-Nunez A, Valle-Casuso JC, Knowlton C, Kim B, Sawyer SL, et al. Effects of human SAMHD1 polymorphisms on HIV-1 susceptibility. Virology. 2014; 460-461: 34-44.
86. Coon S, Wang D, Wu L. Polymorphisms of the SAMHD1 gene are not associated with the infection and natural control of HIV type 1 in Europeans and African-Americans. AIDS research and human retroviruses. 2012; 28(12): 1565-73.
87. Riveira-Munoz E, Ruiz A, Pauls E, Permanyer M, Badia R, Mothe B, et al. Increased expression of SAMHD1 in a subset of HIV-1 elite controllers. The Journal of antimicrobial chemotherapy. 2014; 69(11): 3057-60.
88. Buchanan EL, McAlexander MA, Witwer KW. SAMHD1 expression in blood cells of HIV-1 elite suppressors and viraemic progressors. The Journal of antimicrobial chemotherapy. 2014.
89. Leng J, Ho HP, Buzon MJ, Pereyra F, Walker BD, Yu XG, et al. A cell-intrinsic inhibitor of HIV-1 reverse transcription in CD4(+) T cells from elite controllers. Cell host & microbe. 2014; 15(6): 717- 28.
90. Abdel-Mohsen M, Wang C, Strain MC, Lada SM, Deng X, Cockerham LR, et al. Select host restriction factors are associated with HIV persistence during antiretroviral therapy. Aids. 2015; 29(4): 411-20.
91. Buzon MJ, Seiss K, Weiss R, Brass AL, Rosenberg ES, Pereyra F, et al. Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers. Journal of virology. 2011; 85(18): 9646-50.
92. Esnault C, Heidmann O, Delebecque F, Dewannieux M, Ribet D, Hance AJ, et al. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature. 2005; 433(7024): 430-3.
93. Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR. APOBEC3A and APOBEC3B are potent inhibitors of LTRretrotransposon function in human cells. Nucleic Acids Res. 2006; 34(1): 89-95.
94. LaRue RS, Andresdottir V, Blanchard Y, Conticello SG, Derse D, Emerman M, et al. Guidelines for naming nonprimate APOBEC3 genes and proteins. Journal of virology. 2009; 83(2): 494-7.
95. Berger G, Durand S, Fargier G, Nguyen XN, Cordeil S, Bouaziz S, et al. APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog. 2011; 7(9): e1002221.
96. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. Journal of virology. 2011; 85(21): 11220-34.
97. Koning FA, Goujon C, Bauby H, Malim MH. Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. Journal of virology. 2011; 85(24): 13448-52.
98. Chaipan C, Smith JL, Hu WS, Pathak VK. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. Journal of virology. 2013; 87(1): 444-53.
99. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002; 418(6898): 646-50.
100. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. Journal of virology. 2009; 83(18): 9474-85.
101. Peng G, Greenwell-Wild T, Nares S, Jin W, Lei KJ, Rangel ZG, et al. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood. 2007; 110(1): 393-400.
102. Sasada A, Takaori-Kondo A, Shirakawa K, Kobayashi M, Abudu A, Hishizawa M, et al. APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology. 2005; 2: 32.
103. Delebecque F, Suspene R, Calattini S, Casartelli N, Saib A, Froment A, et al. Restriction of foamy viruses by APOBEC cytidine deaminases. Journal of virology. 2006; 80(2): 605-14.
104. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, et al. DNA deamination mediates innate immunity to retroviral infection. Cell. 2003; 113(6): 803-9.
105. Kock J, Blum HE. Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. The Journal of general virology. 2008; 89(Pt 5): 1184-91.
106. Yu Q, Chen D, Konig R, Mariani R, Unutmaz D, Landau NR. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. The Journal of biological chemistry. 2004; 279(51): 53379-86.
107. Dang Y, Wang X, Esselman WJ, Zheng YH. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. Journal of virology. 2006; 80(21): 10522-33.
108. Ooms M, Brayton B, Letko M, Maio SM, Pilcher CD, Hecht FM, et al. HIV-1 Vif adaptation to human APOBEC3H haplotypes. Cell host & microbe. 2013; 14(4): 411-21.
109. Chelico L, Pham P, Calabrese P, Goodman MF. APOBEC3G DNA deaminase acts processively 3' --> 5' on single-stranded DNA. Nat Struct Mol Biol. 2006; 13(5): 392-9.
110. Nowarski R, Britan-Rosich E, Shiloach T, Kotler M. Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat Struct Mol Biol. 2008; 15(10): 1059-66.
111. Yang B, Chen K, Zhang C, Huang S, Zhang H. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. The Journal of biological chemistry. 2007; 282(16): 11667-75.
112. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, Svarovskaia ES, et al. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. Journal of virology. 2007; 81(13): 7099-110.
113. Binka M, Ooms M, Steward M, Simon V. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. Journal of virology. 2012; 86(1): 49-59.
114. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003; 424(6944): 99- 103.
115. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Current biology: CB. 2005; 15(2): 166-70.
116. Holmes RK, Koning FA, Bishop KN, Malim MH. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. The Journal of biological chemistry. 2007; 282(4): 2587-95.
117. Iwatani Y, Chan DS, Wang F, Maynard KS, Sugiura W, Gronenborn AM, et al. Deaminase-independent inhibition of HIV- 1 reverse transcription by APOBEC3G. Nucleic Acids Res. 2007; 35(21): 7096-108.
118. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 2008; 4(12): e1000231.
119. Gillick K, Pollpeter D, Phalora P, Kim EY, Wolinsky SM, Malim MH. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. Journal of virology. 2013; 87(3): 1508-17.
120. Guo F, Cen S, Niu M, Yang Y, Gorelick RJ, Kleiman L. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. Journal of virology. 2007; 81(20): 11322-31.
121. Luo K, Wang T, Liu B, Tian C, Xiao Z, Kappes J, et al. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. Journal of virology. 2007; 81(13): 7238-48.
122. Adolph MB, Webb J, Chelico L. Retroviral restriction factor APOBEC3G delays the initiation of DNA synthesis by HIV-1 reverse transcriptase. PLoS One. 2013; 8(5): e64196.
123. Schumacher AJ, Hache G, Macduff DA, Brown WL, Harris RS. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. Journal of virology. 2008; 82(6): 2652-60.
124. Kobayashi T, Koizumi Y, Takeuchi JS, Misawa N, Kimura Y, Morita S, et al. Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation. Journal of virology. 2014; 88(10): 5881-7.
125. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 2003; 114(1): 21-31.
126. Reddy K, Winkler CA, Werner L, Mlisana K, Abdool Karim SS, Ndung'u T, et al. APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. Aids. 2010; 24(2): 195-204.
127. Singh KK, Wang Y, Gray KP, Farhad M, Brummel S, Fenton T, et al. Genetic variants in the host restriction factor APOBEC3G are associated with HIV-1-related disease progression and central nervous system impairment in children. Journal of acquired immune deficiency syndromes. 2013; 62(2): 197-203.
128. Bunupuradah T, Imahashi M, Iampornsin T, Matsuoka K, Iwatani Y, Puthanakit T, et al. Association of APOBEC3G genotypes and CD4 decline in Thai and Cambodian HIV-infected children with moderate immune deficiency. AIDS research and therapy. 2012; 9(1): 34.
129. An P, Bleiber G, Duggal P, Nelson G, May M, Mangeat B, et al. APOBEC3G genetic variants and their influence on the progression to AIDS. Journal of virology. 2004; 78(20): 11070-6.
130. Jin X, Brooks A, Chen H, Bennett R, Reichman R, Smith H. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. Journal of virology. 2005; 79(17): 11513-6.
131. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, et al. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. Journal of virology. 2006; 80(18): 9259-69.
132. Ulenga NK, Sarr AD, Thakore-Meloni S, Sankale JL, Eisen G, Kanki PJ. Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. The Journal of infectious diseases. 2008; 198(4): 486-92.
133. Biasin M, Piacentini L, Lo Caputo S, Kanari Y, Magri G, Trabattoni D, et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. The Journal of infectious diseases. 2007; 195(7): 960-4.
134. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, Embree JE, et al. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. Journal of virology. 2008; 82(16): 8172-82.
135. Vazquez-Perez JA, Ormsby CE, Hernandez-Juan R, Torres KJ, Reyes-Teran G. APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology. 2009; 6: 23.
136. Amoedo ND, Afonso AO, Cunha SM, Oliveira RH, Machado ES, Soares MA. Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression. PLoS One. 2011; 6(8): e24118.
137. Cho SJ, Drechsler H, Burke RC, Arens MQ, Powderly W, Davidson NO. APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. Journal of virology. 2006; 80(4): 2069-72.
138. Eyzaguirre LM, Charurat M, Redfield RR, Blattner WA, Carr JK, Sajadi MM. Elevated hypermutation levels in HIV-1 natural viral suppressors. Virology. 2013; 443(2): 306-12.
139. De Pasquale M, Kourteva Y, Allos T, D'Aquila RT. Lower HIV provirus levels are associated with more APOBEC3G protein in blood resting memory CD4+ T lymphocytes of controllers in vivo. PLoS One. 2013; 8(10): e76002.
140. Kourteva Y, De Pasquale M, Allos T, McMunn C, D'Aquila RT. APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo. Virology. 2012; 430(1): 1-9.
141. Sakurai D, Iwatani Y, Ohtani H, Naruse TK, Terunuma H, Sugiura W, et al. APOBEC3H polymorphisms associated with the susceptibility to HIV-1 infection and AIDS progression in Japanese. Immunogenetics. 2015; 67(4): 253-7.
142. Abdel-Mohsen M, Raposo RA, Deng X, Li M, Liegler T, Sinclair E, et al. Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology. 2013; 10: 106.
143. Holzinger D, Jorns C, Stertz S, Boisson-Dupuis S, Thimme R, Weidmann M, et al. Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling. Journal of virology. 2007; 81(14): 7776-85.
144. Rennie ML, McKelvie SA, Bulloch EM, Kingston RL. Transient dimerization of human MxA promotes GTP hydrolysis, resulting in a mechanical power stroke. Structure. 2014; 22(10): 1433-45.
145. Lindenmann J. Resistance of mice to mouse-adapted influenza A virus. Virology. 1962; 16: 203-4.
146. Melen K, Keskinen P, Ronni T, Sareneva T, Lounatmaa K, Julkunen I. Human MxB protein, an interferon-alpha-inducible GTPase, contains a nuclear targeting signal and is localized in the heterochromatin region beneath the nuclear envelope. The Journal of biological chemistry. 1996; 271(38): 23478-86.
147. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011; 472(7344): 481-5.
148. Goujon C, Moncorge O, Bauby H, Doyle T, Ward CC, Schaller T, et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature. 2013; 502(7472): 559-62.
149. Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, Wilson SJ, et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature. 2013; 502(7472): 563-6.
150. Fricke T, White TE, Schulte B, de Souza Aranha Vieira DA, Dharan A, Campbell EM, et al. MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1. Retrovirology. 2014; 11(1): 68.
151. Matreyek KA, Wang W, Serrao E, Singh P, Levin HL, Engelman A. Host and viral determinants for MxB restriction of HIV-1 infection. Retrovirology. 2014; 11(1): 90.
152. Kong J, Xu B, Wei W, Wang X, Xie W, Yu XF. Characterization of the amino-terminal domain of Mx2/MxB-dependent interaction with the HIV-1 capsid. Protein Cell. 2014; 5(12): 954-7.
153. Fricke T, White TE, Schulte B, de Souza Aranha Vieira DA, Dharan A, Campbell EM, et al. MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1. Retrovirology. 2014; 11: 68.
154. Liu Z, Pan Q, Liang Z, Qiao W, Cen S, Liang C. The highly polymorphic cyclophilin A-binding loop in HIV-1 capsid modulates viral resistance to MxB. Retrovirology. 2015; 12(1): 1.
155. Liu Z, Pan Q, Ding S, Qian J, Xu F, Zhou J, et al. The interferoninducible MxB protein inhibits HIV-1 infection. Cell host & microbe. 2013; 14(4): 398-410.
156. Stein DR, Shaw SY, McKinnon LR, Abou M, McCorrister SJ, Westmacott GR, et al. Mx2 expression is associated with reduced susceptibility to HIV infection in highly exposed HIV seronegative Kenyan sex workers. Aids. 2015; 29(1): 35-41.
157. Sironi M, Biasin M, Cagliani R, Gnudi F, Saulle I, Ibba S, et al. Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection. Mol Biol Evol. 2014; 31(9): 2402-14.
158. Sivaramakrishnan G, Sun Y, Tan SK, Lin VC. Dynamic localization of tripartite motif-containing 22 in nuclear and nucleolar bodies. Experimental cell research. 2009; 315(8): 1521- 32.
159. Herr AM, Dressel R, Walter L. Different subcellular localisations of TRIM22 suggest species-specific function. Immunogenetics. 2009; 61(4): 271-80.
160. Gao B, Duan Z, Xu W, Xiong S. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology. 2009; 50(2): 424-33.
161. Barr SD, Smiley JR, Bushman FD. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog. 2008; 4(2): e1000007.
162. Tissot C, Mechti N. Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. The Journal of biological chemistry. 1995; 270(25): 14891-8.
163. Zirn B, Hartmann O, Samans B, Krause M, Wittmann S, Mertens F, et al. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. International journal of cancer Journal international du cancer. 2006; 118(8): 1954-62.
164. Deng YJ, Huang ZX, Zhou CJ, Wang JW, You Y, Song ZQ, et al. Gene profiling involved in immature CD4+ T lymphocyte responsible for systemic lupus erythematosus. Molecular immunology. 2006; 43(9): 1497-507.
165. Eldin P, Papon L, Oteiza A, Brocchi E, Lawson TG, Mechti N. TRIM22 E3 ubiquitin ligase activity is required to mediate antiviral activity against encephalomyocarditis virus. The Journal of general virology. 2009; 90(Pt 3): 536-45.
166. Singh R, Gaiha G, Werner L, McKim K, Mlisana K, Luban J, et al. Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. Journal of virology. 2011; 85(1): 208-16.
167. Kajaste-Rudnitski A, Marelli SS, Pultrone C, Pertel T, Uchil PD, Mechti N, et al. TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NFkappaB- responsive long terminal repeat elements. Journal of virology. 2011; 85(10): 5183-96.
168. Singh R, Patel V, Mureithi MW, Naranbhai V, Ramsuran D, Tulsi S, et al. TRIM5alpha and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment. Journal of virology. 2014; 88(8): 4291-303.
169. Ghezzi S, Galli L, Kajaste-Rudnitski A, Turrini F, Marelli S, Toniolo D, et al. Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease. Aids. 2013; 27(15): 2335-44.
170. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic. 2003; 4(10): 694-709.
171. Blasius AL, Giurisato E, Cella M, Schreiber RD, Shaw AS, Colonna M. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. Journal of immunology. 2006; 177(5): 3260-5.
172. Cobos Jimenez V, Booiman T, de Taeye SW, van Dort KA, Rits MA, Hamann J, et al. Differential expression of HIV-1 interfering factors in monocyte-derived macrophages stimulated with polarizing cytokines or interferons. Scientific reports. 2012; 2: 763.
173. Amet T, Byrd D, Hu N, Sun Q, Li F, Zhao Y, et al. BST-2 expression in human hepatocytes is inducible by all three types of interferons and restricts production of hepatitis C virus. Current molecular medicine. 2014; 14(3): 349-60.
174. Kawai S, Azuma Y, Fujii E, Furugaki K, Ozaki S, Matsumoto T, et al. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer science. 2008; 99(12): 2461-6.
175. Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y, et al. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. Journal of virology. 2009; 83(4): 1837-44.
176. Radoshitzky SR, Dong L, Chi X, Clester JC, Retterer C, Spurgers K, et al. Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. Journal of virology. 2010; 84(20): 10569-80.
177. Kong WS, Irie T, Yoshida A, Kawabata R, Kadoi T, Sakaguchi T. Inhibition of virus-like particle release of Sendai virus and Nipah virus, but not that of mumps virus, by tetherin/CD317/BST-2. Hiroshima journal of medical sciences. 2012; 61(3): 59-67.
178. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008; 451(7177): 425- 30.
179. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell host & microbe. 2008; 3(4): 245-52.
180. Galao RP, Le Tortorec A, Pickering S, Kueck T, Neil SJ. Innate sensing of HIV-1 assembly by Tetherin induces NFkappaBdependent proinflammatory responses. Cell host & microbe. 2012; 12(5): 633-44.
181. Sauter D, Hotter D, Engelhart S, Giehler F, Kieser A, Kubisch C, et al. A rare missense variant abrogates the signaling activity of tetherin/BST-2 without affecting its effect on virus release. Retrovirology. 2013; 10: 85.
182. Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R, Guatelli J. Stimulation of NF-kappaB activity by the HIV restriction factor BST2. Journal of virology. 2013; 87(4): 2046-57.
183. Kluge SF, Mack K, Iyer SS, Pujol FM, Heigele A, Learn GH, et al. Nef proteins of epidemic HIV-1 group O strains antagonize human tetherin. Cell host & microbe. 2014; 16(5): 639-50.
184. Le Tortorec A, Willey S, Neil SJ. Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction. Viruses. 2011; 3(5): 520-40.
185. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, et al. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 2009; 5(5): e1000429.
186. Le Tortorec A, Neil SJ. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. Journal of virology. 2009; 83(22): 11966-78.
187. Dube M, Roy BB, Guiot-Guillain P, Mercier J, Binette J, Leung G, et al. Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. Journal of virology. 2009; 83(9): 4574-90.
188. McNatt MW, Zang T, Bieniasz PD. Vpu binds directly to tetherin and displaces it from nascent virions. PLoS Pathog. 2013; 9(4): e1003299.
189. Cocka LJ, Bates P. Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog. 2012; 8(9): e1002931.
190. Jolly C, Booth NJ, Neil SJ. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. Journal of virology. 2010; 84(23): 12185-99.
191. Mous K, Jennes W, Camara M, Seydi M, Daneau G, Mboup S, et al. Expression analysis of LEDGF/p75, APOBEC3G, TRIM5alpha, and tetherin in a Senegalese cohort of HIV-1-exposed seronegative individuals. PLoS One. 2012; 7(3): e33934.
192. Laplana M, Caruz A, Pineda JA, Puig T, Fibla J. Association of BST-2 gene variants with HIV disease progression underscores the role of BST-2 in HIV type 1 infection. The Journal of infectious diseases. 2013; 207(3): 411-9.
193. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, et al. Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(8): 3035-40.
194. Raposo RA, Abdel-Mohsen M, Holditch SJ, Kuebler PJ, Cheng RG, Eriksson EM, et al. Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals. Journal of leukocyte biology. 2013; 94(5): 1051-9.
195. Pham QT, Veillette M, Brandariz-Nunez A, Pawlica P, Thibert- Lefebvre C, Chandonnet N, et al. A novel aminoacid determinant of HIV-1 restriction in the TRIM5alpha variable 1 region isolated in a random mutagenic screen. Virus research. 2013; 173(2): 306- 14.
196. Neagu MR, Ziegler P, Pertel T, Strambio-De-Castillia C, Grutter C, Martinetti G, et al. Potent inhibition of HIV-1 by TRIM5- cyclophilin fusion proteins engineered from human components. The Journal of clinical investigation. 2009; 119(10): 3035-47.